Menu

Tenacity

We are bold and optimistic as we work to better the life of each person impacted by kidney disease

Innovation

Making a difference by
challenging the status quo

Collaboration

We are better together

;

A trusted leader in the renal community delivering new therapeutic options to people with kidney disease.

We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, in global Phase 3 clinical development. Vadadustat and HIF-PHI are based on Nobel Prize-winning science.

Vadadustat is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.

Be part of a passionate team working to protect the kidneys and to innovate for better lives

Nearly 37 million Americans

are currently affected by chronic kidney disease.

Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible.

Reference
Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Available at: https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html. Accessed: September 3, 2019.

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us